Tupharma Connect and Trade SRL
Tupharma Connect and Trade reported total assets of 95,322 € at the end of the 2026 financial year (annual accounts filed with the NBB on 14 Oct 2026).
The score of Tupharma Connect and Trade shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2026
Change 2023 → 2026: Total assets -61 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Tupharma Connect and Trade's annual accounts
Filed annual accounts
- Year ended 31 Mar 2026filed on 14 Oct 2026
- Year ended 31 Mar 2025filed on 26 Sep 2025
- Year ended 31 Mar 2024filed on 08 Nov 2024
- Year ended 31 Mar 2023filed on 19 Nov 2023
- Year ended 31 Mar 2022filed on 30 Oct 2022
Tupharma Connect and Trade's financial analysis
- Solvency-51.0%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Tupharma Connect and Trade
Tupharma Connect and Trade's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0745.588.619
- VAT number
- BE0745588619
- Peppol
- Registered · 0208:0745588619 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 23 Mar 2020
- Registered office
- 9040 Ghent
- Latest accounts
- 2026 · filed on 14 Oct 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Tupharma Connect and Trade (SRL) has been based in Ghent since 2020, active in: retail sale of pharmaceutical products. For 2026, it reports a net loss of 33,494 € and equity of −48,620 €; its revenue is not published. Its solvency stands at -51.0%, below the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Tupharma Connect and Trade
Companies in the same business, of comparable size and area, outside its group.
- ACP-Pharma Retail sale of pharmaceutical products Affligem · balance sheet 48,017 €
- Pharm'Training Lab Retail sale of pharmaceutical products Leuze-en-Hainaut · balance sheet 87,540 €
- Farmacyze Retail sale of pharmaceutical products Ostend · balance sheet 73,863 €
- Temapharm Retail sale of pharmaceutical products Neupré · balance sheet 191,548 €
- LEND Retail sale of pharmaceutical products Herent · balance sheet 168,624 €
- Alpagota Retail sale of other new goods Antwerp · balance sheet 103,211 €
- Antha Consult Retail sale of pharmaceutical products Liège · balance sheet 272,102 €
- Eliam Retail sale of pharmaceutical products Hasselt · balance sheet 122,187 €
Frequently asked questions about Tupharma Connect and Trade
What is the revenue of Tupharma Connect and Trade?
Tupharma Connect and Trade files its accounts in a format where revenue is optional: it is not published for 2026.
What is the VAT number of Tupharma Connect and Trade?
In Belgium, the VAT number is the company number prefixed with BE: BE0745588619 for Tupharma Connect and Trade, if the company is VAT-registered. Its company number (CBE) is 0745.588.619.
Where is the registered office of Tupharma Connect and Trade?
According to the CBE register, the registered office of Tupharma Connect and Trade is in 9040 Ghent.
What is the equity of Tupharma Connect and Trade?
At the close of the 2026 financial year, the equity of Tupharma Connect and Trade amounts to -48,620 €, a solvency of -51.0% of total assets.
Who manages Tupharma Connect and Trade?
The register lists 1 active mandates at Tupharma Connect and Trade. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Tupharma Connect and Trade
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →